Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs) EQUITY
$68.15
pos +1.10
+1.70%
Today's Range: 65.03 - 68.45 | BMRN Avg Daily Volume: 1,693,700
Last Update: 02/11/16 - 12:11 PM EST
Volume: 534,533
YTD Performance: -36.01%
Open: $66.41
Previous Close: $67.02
52 Week Range: $62.12 - $151.75
Oustanding Shares: 161,251,715
Market Cap: 10,499,099,164
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 1 1 1 1
Hold 4 4 4 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.64 1.64 1.64 1.54
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -32.72
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-32.72 0.00 27.19
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-40.30% -29.26% 21.87%
GROWTH 12 Mo 3 Yr CAGR
Revenue 36.90 0.70 0.19
Net Income 0.00 1.49 0.00
EPS 0.00 0.92 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.75B
Average Earnings Estimates
Qtr (12/15) Qtr (03/16) FY (12/15) FY (12/16)
Average Estimate $1.00 $-0.96 $-0.46 $-2.07
Number of Analysts 12 7 11 13
High Estimate $1.58 $-0.40 $0.26 $-1.12
Low Estimate $0.81 $-2.94 $-0.65 $-4.40
Prior Year $-0.30 $-0.25 $-0.77 $-0.46
Growth Rate (Year over Year) 434.17% -282.86% 39.91% -346.85%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | Feb 8, 2016 | 11:46 AM EST

BMRN could re-base in the weeks and months ahead as downside looks limited. 

By

Tony Owusu

 | Nov 22, 2015 | 8:05 PM EST

Also, Pfizer-Allergan deal clears another hurdle.

By

Jim Cramer

 | Oct 15, 2015 | 3:02 PM EDT

Once again, buyers are going for the gusto.

By

Jim Cramer

 | Oct 13, 2015 | 2:55 PM EDT

Drug companies are just too big a target to ignore.

By

Jim Cramer

 | Aug 31, 2015 | 11:12 AM EDT

Which means interest rate hikes are being built into prices.

By

Bob Byrne

 | Aug 10, 2015 | 7:00 AM EDT

The bulls can show them around the place.

By

Jim Cramer

 | Aug 4, 2015 | 12:47 PM EDT

Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.

By

Sebastian Silva

 | Aug 2, 2015 | 7:39 PM EDT

Coal and renewables could both react as political and legal battles ensue.

By

Robert Lang

 | Jul 10, 2015 | 10:00 AM EDT

BioMarin's chart has a well-defined uptrend line and shows great relative strength.

By

Robert Lang

 | Jun 22, 2015 | 10:00 AM EDT

I like BioMarin because it has more upside and solid Relative Strength.

Well said, Jim C. To me it isn't so much as the Federal Reserve is missing a moment as we ...

Possible SEC accounting investigation

The top three biotechnology picks we have at Shark Biotechnology right now are FGEN, RARE ...
Here is my cost basis in today's biotech buys: XON $29.99 SAGE $29.09 PTLA $29.29 OTIC ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.